Leanne Ward

Dr. Leanne Ward

Co-Applicant

Professor of Pediatrics and Tier 1 Clinical Research Chair in Pediatric Bone Disorders at uOttawa | Medical Director of the CHEO Genetic and Metabolic Bone Disease Clinic

Scientific Director of the Ottawa Pediatric Bone Health Research Group | Pediatric Endocrinologist at CHEO


NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research

Email Leanne

Research Interests: children, osteoporosis, osteogenesis imperfecta, bisphosphonate therapy, skeletal dysplasias, bone health, fractures, bone density, glucocorticoid-induced osteoporosis, x-linked hypophosphatemia, achondroplasia, duchenne muscular dystrophy and hypophospha

Academic web profile
Google Scholar profile

Biography

Dr. Leanne Ward is a Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa where she holds a Tier 1 Research Chair in Pediatric Bone Disorders. Dr. Ward is also cross-appointed to the Department of Surgery given strong clinical and research ties to the Division of Orthopedics. She is the Scientific Director of The Ottawa Pediatric Bone Health Research Group, The Medical Director of the Pediatric Osteology Clinic at the Children’s Hospital of Eastern Ontario (CHEO), and a pediatric endocrinologist-osteologist in the CHEO Division of Endocrinology. In 2014, she founded The Canadian Consortium for Children’s Bone Health, a national, multi-disciplinary network of clinicians and scientists that fosters health professional education and research in childhood-onset bone disorders (bonescanada.org). She is also a Steering Committee Member of the International Society of Children’s Bone Health (ISCBH) and the Founder and Director of the Canadian Alliance for Rare Disorders o the Skeleton. 

 

Dr. Ward’s research program is dedicated to the diagnosis and treatment of childhood-onset bone disorders including skeletal dysplasias (i.e. osteogenesis imperfecta and achondroplasia), genetic forms of rickets, hypophosphatasia and osteoporosis due to chronic illnesses (i.e. childhood cancer and Duchenne muscular dystrophy). The Ward lab has a particular focus on therapeutic trials in childhood-onset bone disorders, emphasizing skeletal health outcomes quantified through central skeletal imaging, and the study of novel drugs to mitigate the functional consequences of rare bone diseases. The Ward lab’s signature is local-to-global collaborative engagement with clinicians, researchers and the patient community in key areas that span orthopedics, genetics, radiology, endocrinology, dentistry, audiology, allied health, biomedical statistics and clinical trial operations.   

 

Dr. Ward has held sustained funding from the Canadian Institutes of Health Research since 2003, published over 300 book chapters, abstracts and manuscripts, and delivered over 130 international invited speaking engagements. She works closely with patient advocacy groups to promote patient education and access to rare disease care, including the Canadian Organization for Rare Disorders, The Canadian Osteogenesis Imperfecta Society, The Canadian XLH Network, Parent Project Muscular Dystrophy, Defeat Duchenne Canada and Soft Bones Canada. In 2019, Dr. Ward was named a Fellow of the American Society of Bone and Mineral Research, an award in recognition of significant lifetime contributions to bone and mineral science.  

 


Recent Publications

Ludwig, K, Wu, Z, Bardai, G, Miranda, V, Alos, N, Ward, LM et al.. RNA-First Approach Identifies Deep Intronic PHEX Variants in X-Linked Hypophosphatemic Rickets. J Clin Endocrinol Metab. 2024. PMID:39512182

Deschênes, ÉR, Do, J, Tsampalieros, A, Webster, RJ, Whitley, N, Ward, LM et al.. Pediatric Headache Patients Are at High Risk of Vitamin D Insufficiency. J Child Neurol. 2024. 8830738241284057 PMID:39380442

Voermans, NC, Dittrich, ATM, Liguori, S, Panicucci, C, Moretti, A, Weber, DR et al.. 274th ENMC international workshop: recommendations for optimizing bone strength in neuromuscular disorders. Hoofddorp, The Netherlands, 19-21 January 2024. Neuromuscul Disord. 2024.43 1-13 PMID:39173540

Portale, AA, Ward, L, Dahir, K, Florenzano, P, Ing, SW, Jan de Beur, SM et al.. Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study. J Bone Miner Res. 2024.39 (10)1493-1502 PMID:39151033

Ward, LM, Bakhamis, S, Koujok, K. Approach to the Pediatric Patient with Glucocorticoid-Induced Osteoporosis. J Clin Endocrinol Metab. 2024. PMID:39126675

Ahmet, A, Tobin, R, Dang, UJ, Rooman, R, Guglieri, M, Clemens, PR et al.. Adrenal suppression from vamorolone and prednisone in Duchenne muscular dystrophy: results from the phase 2b clinical trial. J Clin Endocrinol Metab. 2024. PMID:39097643

Ward, LM, Högler, W, Glorieux, FH, Portale, AA, Whyte, MP, Munns, CF et al.. Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. JBMR Plus. 2024.8 (1)ziad001 PMID:38690124

Khan, AA, Brandi, ML, Rush, ET, Ali, DS, Al-Alwani, H, Almonaei, K et al.. Correction: Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos Int. 2024.35 (5)933-934 PMID:38498158

Ward, LM. A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence. Front Endocrinol (Lausanne). 2023.14 1266986 PMID:38374961

Dang, UJ, Damsker, JM, Guglieri, M, Clemens, PR, Perlman, SJ, Smith, EC et al.. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. Neurology. 2024.102 (5)e208112 PMID:38335499

See more on PubMed